Sucampo Reports Positive Results from Phase 2a Study of Intravenous Ion Channel Activator for Lumbar Spinal Stenosis

Sucampo Pharmaceuticals (Nasdaq: SCMP ) today announced the results of its double-blind, placebo-controlled Phase 2a proof of concept study evaluating safety and efficacy of an intravenously (IV) administered compound of the company's proprietary ion channel activator program in patients with lumbar spinal stenosis (LSS). A responder analysis of data